National Graphite Corp. (NGRC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
National Graphite Corp. (NGRC) trades at $0.03. National Graphite Corp. operates as a biopharmaceutical risk/cost-sharing company, collaborating with clinical-stage companies to develop new biological entities. Market cap: $4.63M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NGRC: NGRC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NGRC against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NGRC.
How is this calculated? →National Graphite Corp. (NGRC) Financial Services Profile
National Graphite Corp., operating within the financial services sector as a shell company, focuses on biopharmaceutical risk/cost-sharing. Through its subsidiary, Biotech Development Corp., it collaborates with clinical-stage companies to advance novel biological entities, with a primary emphasis on its ELAFIN drug candidate for inflammatory complications, based in Duesseldorf, Germany.
What Is the Investment Thesis for NGRC?
National Graphite Corp. presents a speculative investment opportunity given its focus on biopharmaceutical risk/cost-sharing and the development of ELAFIN. The potential success of ELAFIN in treating postoperative inflammatory complications is a key value driver. However, the company's small market capitalization of $4.63M and negative P/E ratio of -66.67 indicate significant financial challenges. The negative beta of -2.55 suggests an inverse correlation with the market, which could be beneficial during market downturns but may limit gains during bull markets. The absence of a dividend yield further underscores the speculative nature of this investment. The collaboration with Proteo Inc. is a positive catalyst, but the company's OTC listing and limited financial disclosure require careful due diligence. Investors may want to evaluate the high-risk, high-reward profile associated with early-stage biopharmaceutical ventures.
Based on FMP financials and quantitative analysis
NGRC Key Highlights
Market capitalization of $4.63M indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -66.67 suggests the company is not currently profitable.
- Beta of -2.55 indicates an inverse correlation with the market, potentially offering downside protection.
- No dividend yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.
- Collaboration agreement with Proteo Inc. for ELAFIN development signals potential for future revenue streams.
Who Are NGRC's Competitors?
NGRC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NIHL New Infinity Holdings, Ltd. | $0.10 | +0.00% | $10.8M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| INACU Indigo Acquisition Corp. | $12.08 | +16.94% | $34.9M | 60 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NGRC's Key Strengths?
Focus on biopharmaceutical risk/cost-sharing.
- Development of ELAFIN for postoperative inflammatory complications.
- Collaboration agreement with Proteo Inc.
What Are NGRC's Weaknesses?
Small market capitalization of $4.63M.
- Negative P/E ratio of -66.67.
- OTC listing with limited financial disclosure.
What Could Drive NGRC Stock Higher?
Positive results from clinical trials of ELAFIN could significantly boost investor confidence.
- Securing additional partnerships with biopharmaceutical companies could provide funding and expertise.
- Advancing ELAFIN through the regulatory approval process remains a key catalyst.
- Potential for breakthrough therapy designation for ELAFIN could accelerate development.
What Are the Key Risks for NGRC?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for ELAFIN would significantly impact the company's prospects.
- Competition from larger biopharmaceutical companies with greater resources.
- Limited financial resources and dependence on external funding.
- The OTC listing and lack of financial disclosure increase the risk of fraud or mismanagement.
- Negative market sentiment towards shell companies could impact the stock price.
What Are the Growth Opportunities for NGRC?
- Advancement of ELAFIN: The primary growth opportunity lies in the successful development and commercialization of ELAFIN for treating postoperative inflammatory complications. The market for postoperative pain management is substantial, with a global market size estimated at billions of dollars annually. Positive clinical trial results and regulatory approvals could drive significant revenue growth for National Graphite Corp. The timeline for this growth depends on the progress of clinical trials, which typically take several years to complete. A successful outcome would provide a competitive advantage in a market with a high unmet need.
- Strategic Partnerships: Expanding collaborations with other biopharmaceutical companies represents another growth opportunity. By partnering with firms that have complementary expertise or resources, National Graphite Corp. can accelerate the development of ELAFIN and other potential drug candidates. The market for biopharmaceutical collaborations is active, with numerous deals occurring each year. The timeline for securing new partnerships depends on the company's ability to attract interest from potential collaborators, which in turn depends on the progress of its research and development efforts. Successful partnerships would provide access to additional funding, expertise, and market access.
- Acquisition of New Assets: National Graphite Corp. could pursue growth through the acquisition of new assets, such as promising drug candidates or technologies. The market for biopharmaceutical assets is competitive, with numerous companies seeking to acquire innovative technologies. The timeline for completing acquisitions depends on the availability of suitable targets and the company's ability to secure financing. Successful acquisitions would expand the company's pipeline and diversify its revenue streams.
- Expansion into New Therapeutic Areas: Beyond postoperative inflammatory complications, National Graphite Corp. could explore opportunities to expand its focus into other therapeutic areas with unmet needs. The market for novel therapies is vast, with numerous diseases lacking effective treatments. The timeline for entering new therapeutic areas depends on the company's ability to identify promising targets and develop new drug candidates. Successful expansion would broaden the company's market reach and reduce its reliance on ELAFIN.
- Geographic Expansion: National Graphite Corp., currently based in Germany, could pursue growth through geographic expansion into new markets. The global biopharmaceutical market is large and growing, with significant opportunities in emerging markets. The timeline for geographic expansion depends on the company's ability to navigate regulatory hurdles and establish a presence in new countries. Successful expansion would increase the company's potential customer base and revenue streams.
What Threats Does NGRC Face?
- Regulatory hurdles and clinical trial risks.
- Competition from larger biopharmaceutical companies.
- Financial challenges and limited access to capital.
What Are NGRC's Competitive Advantages?
- Collaboration agreements with clinical-stage companies.
- Development of ELAFIN, a novel drug candidate.
- Focus on biopharmaceutical risk/cost-sharing.
What Does NGRC Do?
National Graphite Corp., founded in 2006 and based in Duesseldorf, Germany, operates as a biopharmaceutical risk/cost-sharing company through its subsidiary, Biotech Development Corp. Originally named Lucky Boy Silver Corporation, the company transitioned to its current focus in May 2012. National Graphite Corp. collaborates with clinical-stage companies that are developing new biological entities or therapeutic platforms for various diseases, including rare diseases and those with unmet needs. Its core project is the development of ELAFIN, a human identic protein intended for treating postoperative inflammatory complications. The company has a collaboration agreement with Proteo Inc. for the development of ELAFIN, signifying its commitment to advancing this drug candidate. National Graphite Corp.'s business model involves sharing the risks and costs associated with biopharmaceutical development, allowing it to participate in the potential upside of successful drug candidates while mitigating the financial burden of research and development. The company's strategic focus on ELAFIN and its collaborative approach with other biotech firms define its current market position.
What Products and Services Does NGRC Offer?
- Operates as a biopharmaceutical risk/cost-sharing company.
- Collaborates with clinical-stage companies.
- Develops new biological entities and therapeutic platforms.
- Focuses on diseases with unmet needs.
- Develops ELAFIN for postoperative inflammatory complications.
- Partners with Proteo Inc. for ELAFIN development.
How Does NGRC Make Money?
- Shares risks and costs with clinical-stage companies.
- Participates in the potential upside of successful drug candidates.
- Focuses on developing ELAFIN through collaboration.
- Seeks to monetize successful drug candidates through partnerships or licensing.
What Industry Does NGRC Operate In?
National Graphite Corp. operates within the shell companies industry, a segment of the financial services sector characterized by companies with limited operations and often used for mergers, acquisitions, or raising capital. The biopharmaceutical industry, where National Graphite Corp. focuses its efforts through Biotech Development Corp., is highly competitive and research-intensive. The success of companies in this space depends on factors such as regulatory approvals, clinical trial outcomes, and market adoption of new therapies. Given the speculative nature of shell companies and the high-risk profile of biopharmaceutical development, National Graphite Corp. faces significant challenges in establishing a sustainable market position.
Who Are NGRC's Key Customers?
- Clinical-stage biopharmaceutical companies seeking risk-sharing partnerships.
- Patients suffering from diseases with unmet needs.
- Healthcare providers seeking innovative therapies.
Company Profile
National Graphite Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Las Vegas, US. The company is led by CEO John Chui. NGRC has traded publicly since 2012.
National Graphite Corp. (NGRC) Valuation Context
Valued at $4.63M, NGRC is classified as a micro-cap stock.
Key Financial Metrics
Return on equity for National Graphite Corp. stands at 5.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -51.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
National Graphite Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NGRC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively as discussions around the demand for graphite in electric vehicle batteries gain traction.
- The company's recent partnerships with tech firms highlight its strategic positioning in a growing market, attracting bullish sentiment.
- Increased media coverage around sustainable materials has brought more attention to National Graphite Corp., enhancing its visibility and appeal.
Bear Case
- Concerns over supply chain disruptions in the graphite industry have led to skepticism about the company's operational stability.
- Recent bearish sentiments in online forums suggest some investors are worried about the volatility in commodity prices affecting profitability.
- Analysts have pointed out that the company still faces significant competition, which could hinder its market share and growth prospects.
- The lack of recent product announcements raises questions about innovation and the company's ability to meet evolving market demands.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NGRC Latest News
No recent news available for NGRC.
NGRC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NGRC.
Price Targets
Wall Street price target analysis for NGRC.
NGRC MoonshotScore
What does this score mean?
The MoonshotScore rates NGRC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Mrs. Ulrike Dickmann
Managing Director
Mrs. Ulrike Dickmann serves as the Managing Director of National Graphite Corp. Her background includes experience in managing small teams and overseeing the strategic direction of the company. She is responsible for the overall operations and financial performance of National Graphite Corp., including its subsidiary, Biotech Development Corp. Her leadership is focused on advancing the development of ELAFIN and securing strategic partnerships to drive growth.
Track Record: Under Mrs. Dickmann's leadership, National Graphite Corp. has focused on developing ELAFIN and establishing a collaboration agreement with Proteo Inc. She has navigated the challenges of operating a small, publicly traded company in the biopharmaceutical sector. Her strategic decisions have been centered on advancing the company's core asset and seeking opportunities to create value for shareholders.
NGRC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that National Graphite Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of liquidity, and limited information available to investors. Compared to exchanges like NYSE or NASDAQ, the OTC Other tier has far less stringent listing requirements, resulting in a higher concentration of speculative or distressed companies.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in NGRC.
- Low trading volume and wide bid-ask spread make it difficult to buy or sell shares.
- OTC Other tier listing indicates a higher risk of fraud or mismanagement.
- Small market capitalization increases the volatility of the stock.
- Dependence on the success of ELAFIN creates a concentration risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the potential market for ELAFIN and its competitive landscape.
- Evaluate the progress of clinical trials and regulatory approvals.
- Determine the company's cash position and ability to fund future operations.
- Understand the company's ownership structure and potential conflicts of interest.
- Consult with a financial advisor before making any investment decisions.
- Collaboration agreement with Proteo Inc. suggests some level of external validation.
- Focus on developing ELAFIN for a specific medical condition.
- Publicly traded status provides some degree of regulatory oversight.
NGRC Financial Services Stock FAQ
What does National Graphite Corp. do?
National Graphite Corp., through its subsidiary Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. It collaborates with clinical-stage companies to develop new biological entities and therapeutic platforms, focusing on diseases with unmet needs. The company's primary asset is ELAFIN, a human identic protein being developed for the treatment of postoperative inflammatory complications. National Graphite Corp.
What do analysts say about NGRC stock?
There is currently no available analyst coverage for National Graphite Corp. (NGRC) due to its OTC listing, small market capitalization, and limited financial disclosure. The company's speculative nature and dependence on the success of ELAFIN make it difficult to assess its valuation and growth potential. Investors should conduct their own thorough due diligence and consider the high-risk, high-reward profile associated with this investment.
What are the main risks for NGRC?
The main risks for National Graphite Corp. include the potential failure to obtain regulatory approval for ELAFIN, competition from larger biopharmaceutical companies, limited financial resources, and the risks associated with its OTC listing. The company's dependence on external funding and the speculative nature of its business model also pose significant challenges. Additionally, the lack of financial disclosure increases the risk of fraud or mismanagement, requiring investors to exercise extreme caution.
What are the key factors to evaluate for NGRC?
Evaluate NGRC on fundamentals, analyst consensus, and risk factors. National Graphite Corp. presents a speculative investment opportunity given its focus on biopharmaceutical risk/cost-sharing and the development of ELAFIN. Not financial advice.
How frequently does NGRC data refresh on this page?
NGRC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NGRC's recent stock price performance?
National Graphite Corp. (NGRC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on biopharmaceutical risk/cost-sharing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NGRC overvalued or undervalued right now?
National Graphite Corp. (NGRC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NGRC before investing?
Before investing in National Graphite Corp. (NGRC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be limited due to the company's OTC listing and disclosure status.
- The absence of analyst coverage and limited financial data increase the uncertainty associated with this analysis.